Metabolite-derived artificial polymers designed for drug targeting, cell penetration and bioresorption

被引:29
|
作者
Abdellaoui, K
Boustta, M
Vert, M
Manfait, M
机构
[1] Univ Montpellier 1, Fac Pharm, CNRS, URA 1465,CRBA, F-34060 Montpellier, France
[2] Univ Reims, Fac Pharm, Lab Mol Spect, F-51000 Reims, France
关键词
poly(L-lysine citramide); poly(beta-malic acid); doxorubicin;
D O I
10.1016/S0928-0987(97)00069-9
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The use of poly(beta-malic acid) and poly(L-lysine citramide) carriers to transport doxorubicin (Dox) within K562 myeloblastic cells was studied by taking advantage of laser microspectrofluorometry (L-MSF). This technique provided a means to monitor and to quantify the penetration of Dox molecules in the cytoplasm and in the nucleus of Dox-sensitive and Dox-resistant cells. Comparison was made between polymer-drug conjugates more or less hydrophobised by C2, C7 and C12 aliphatic substituents and by the Dox attached to the polymer backbone as pendent chains. Furthermore, a method was proposed to introduce a cleavable non-peptidic spacer of the lactyllactyl-type between the poly(L-lysine citramide) backbone and the drug. It is shown that: Dox was released from the conjugates by a non-enzymatic route in the absence of cells, the Dox-uptake by cells was slower for the conjugates than for the free drug, and the hydrophobisation promoted the penetration of the released drug within the nucleus, even in the case of Dox-resistant cells. However, no reversion of the resistance was observed. (C) 1998 Elsevier Science B.V.
引用
收藏
页码:61 / 73
页数:13
相关论文
共 39 条
  • [21] Drug Repurposing for Targeting Myeloid-Derived Suppressor-Cell-Generated Immunosuppression in Ovarian Cancer: A Literature Review of Potential Candidates
    Berckmans, Yani
    Hoffert, Yannick
    Vankerckhoven, Ann
    Dreesen, Erwin
    Coosemans, An
    PHARMACEUTICS, 2023, 15 (07)
  • [22] Assessment of tyrosine kinase inhibitor bypass mechanisms in lung cancer using single cell multiomics, patient derived organoids and rationally designed drug screens
    Liu, Liqiong
    Strange, Ann
    Lee, Schuyler
    Gao, Bifeng
    Merrick, Daniel
    Patil, Tejas
    DeGregori, James
    Camidge, D. Ross
    Pine, Sharon R.
    Sabaawy, Hatim E.
    CANCER RESEARCH, 2024, 84 (06)
  • [23] Enhanced tumor self-targeting of lemon-derived extracellular vesicles by embedding homotypic cancer cell membranes for efficient drug delivery
    Yang, Lu-Yao
    Liang, Guo-Wu
    Cai, Bing-Jie
    Xu, Ke-Min
    Zhao, Yu-Jie
    Xie, Xiao-Ting
    Zhang, Yu-Lin
    Li, Chao-Qing
    Zhang, Guo-Jun
    JOURNAL OF NANOBIOTECHNOLOGY, 2025, 23 (01)
  • [24] Methylated urolithin A, the modified ellagitannin-derived metabolite, suppresses cell viability of DU145 human prostate cancer cells via targeting miR-21
    Zhou, Benhong
    Wang, Jing
    Zheng, Guohua
    Qiu, Zhenpeng
    FOOD AND CHEMICAL TOXICOLOGY, 2016, 97 : 375 - 384
  • [25] Chitosan-derived drug free " artificial beacon" simulating immunogenetic cell death cascade effector to initiate immune response for cancer therapy
    Lou, Haiya
    Shang, Xuwei
    Wang, Zixu
    Xiang, Shanshan
    Qiu, Yihe
    Wang, Cheng
    Yu, Fangying
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 287
  • [26] Novel drug candidates cep1430 and cep1507 for targeting pancreatic patient-derived xenograft cancer stem cell and circulating tumor cell models
    Sharma, Michael
    Jain, Maulik
    Sharma, Cristian
    Amezcua, Karina
    Amezcua, Natalee
    Hasson, Reed
    Navel, Miriam
    Stanton, Donna
    Narayan, Satya
    Kramberger, Karl
    Punzalan, Rubio
    Jani, Jitesh
    Foster, Douglas
    Sharma, Jay P.
    CANCER RESEARCH, 2017, 77
  • [27] Targeting hypoxia-mediated gene transcription with a novel polyamide drug designed to disrupt the HIF1α/β heterodimer binding overcomes resistance to hypoxia in myeloma cell lines
    Mysore, Veena S.
    Nickols, Nicholas G.
    Szablowski, Jerzy
    Dervan, Peter
    Lichtenstein, Alan
    Frost, Patrick J.
    CANCER RESEARCH, 2014, 74 (19)
  • [28] Hydrophobicity-Adaptive Polymers Trigger Fission of Tumor-Cell-Derived Microparticles for Enhanced Anticancer Drug Delivery (vol 35, 2211980, 2023)
    Liu, Haojie
    Xu, Shiyi
    Yong, Tuying
    Wei, Zhaohan
    Bie, Nana
    Zhang, Xiaoqiong
    Li, Xin
    Li, Jianye
    Li, Shiyu
    Wang, Sheng
    Zhao, Yanbing
    Yang, Xiangliang
    Gan, Lu
    ADVANCED MATERIALS, 2025,
  • [29] Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate in patient-derived xenograft models
    Wu, Chi-Heng
    Wang, Linlin
    Yang, Chen-Yen
    Wen, Kwun Wah
    Hinds, Brian
    Gill, Ryan
    McCormick, Frank
    Moasser, Mark
    Pincus, Laura
    Ai, Weiyun Z.
    BLOOD ADVANCES, 2022, 6 (07) : 2290 - 2302
  • [30] Cell-specific targeting in the mouse inner ear using nanoparticles conjugated with a neurotrophin-derived peptide ligand: Potential tool for drug delivery
    Roy, Soumen
    Johnston, Alex H.
    Newman, Tracey A.
    Glueckert, Rudolf
    Dudas, Jozsef
    Bitsche, Mario
    Corbacella, Elisa
    Rieger, Gunde
    Martini, Alessandro
    Schrott-Fischer, Anneliese
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 390 (02) : 214 - 224